Related Experiment Video
Updated: Jul 15, 2026
10:29
Mapping Infant Immunity with Minimal Input: Integrative Single-Cell and Multiomic Profiling
Published on: April 3, 2026
Plasma soluble CD30 level correlates negatively with age in children
Jung Yu Chen1, Lin Shien Fu, Jao Jia Chu
1Division of Immunology, Rheumatology and Allergy, Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Summary
CD30 is not a reliable marker for atopic diseases in children, as its levels do not differ between atopic and non-atopic groups. Soluble CD30 (sCD30) levels inversely correlate with age in both groups.
Area of Science:
- Immunology
- Pediatric Allergy
Background:
- Atopic diseases are linked to immune dysregulation, specifically T helper cell type 1/2 (Th1/Th2) imbalances.
- CD30 is hypothesized as a marker for Th2-mediated immunity.
Purpose of the Study:
- To evaluate CD30 as a marker for atopy and Th2 immune predominance in children.
- To investigate the relationship between CD30 expression and atopic status in a pediatric cohort.
Main Methods:
- Assessed surface CD30 expression on T and B lymphocytes in 61 children with atopy and 27 controls.
- Measured plasma soluble CD30 (sCD30) levels in the same participants.
Main Results:
- No significant differences were observed in surface CD30 expression on lymphocytes between atopic and control children.
- Plasma sCD30 levels did not differ between the atopic and control groups.
- A strong negative correlation between sCD30 levels and age was found in both control (r = -0.72) and atopic (r = -0.45) children.
Conclusions:
- CD30 is not a suitable surrogate marker for atopic disease or Th2 immune responses in children.
- Age is a significant factor influencing sCD30 levels and must be considered in future research.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...